Axe Compute Inc. — fact timeline

Axe Compute Inc. reported first quarter ended March 31, 2026 results: revenue $35 thousand, net income $7.7 million, EPS $0.36 per share.

“FIRST QUARTER 2026 FINANCIAL HIGHLIGHTS Total Revenue: $35 thousand in Q1 2026, compared to $110 thousand in Q1 2025. The Q1 2026 sales primarily reflects sales from the legacy Drug Discovery Services segment, with $7 thousand contributed by the Compute Services segment reflecting a handful of initial contract deployments that commenced in late March 2026 and will contribute revenue over the respective contract service periods beyond March 31, 2026.”

Axe Compute Inc. reported the fiscal year ended December 31, 2025 results: revenue $125,284, net income $232.9 million.

“center facilities or GPU hardware; the Company’s platform provides marketplace access to this network on an asset-light model. FULL YEAR 2025 FINANCIAL HIGHLIGHTS Total Revenue: $125,284, derived entirely from the Company’s Drug Discovery Services legacy segment. No compute revenue was recognized in fiscal 2025, as the Axe Compute segment launched in September 2025”

Axe Compute Inc.: Third Amended and Restated Bylaws adopted to reflect new corporate name and integrate prior amendments (effective 2025-12-11).

“the Board approved and adopted the Third Amended and Restated Bylaws, also effective on December 11, 2025 (the “ A&R Bylaws ”), to reflect the corporate name Axe Compute Inc. and to integrate prior amendments to the Company’s bylaws, dated September 9, 2022 (as amended to date, the “ Bylaws ”).”

Axe Compute Inc.: Certificate of Amendment to change corporate name from Predictive Oncology Inc. to Axe Compute Inc (effective 2025-12-11).

“On December 9, 2025, Predictive Oncology Inc. (the “ Company ”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation to change its corporate name from Predictive Oncology Inc. to Axe Compute Inc. (the “ Name Change ”), effective December 11, 2025.”

Axe Compute Inc. issued pre-funded warrants to purchase an aggregate of up to approximately 223.6 million shares of Common Stock of warrant to certain accredited investors for combination of digital assets, including primarily Aethir tokens (ATH).

“On September 29, 2025, the Company, in a separate private placement transaction, entered into a securities purchase agreement (the “ Cryptocurrency Securities Purchase Agreement ” and, together with the Cash Securities Purchase Agreement, the “ Securities Purchase Agreements ”) with certain accredited investors (the “ Cryptocurrency Purchasers ” and, together with the Cash Purchasers, the “ Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cryptocurrency Purchasers in a private placement (the “ Cryptocurrency Offering ” and, together with the Cash Offering, the “ Private Placements ”) pre-funded warrants (the “ Cryptocurrency Pre-Funded Warrants ” and, together with the Cash Pre-Funded Warrants, the “ Pre-Funded Warrants ” and, together with the Cash Securities, the “ Securities ”) to purchase an aggregate of up to approximately 223.6 million shares of Common Stock (the “ Cryptocurrency Pre-Funded Warrant Shares ” and, together with the Cash Pre-Funded Warrant”

Axe Compute Inc. issued pre-funded warrants to purchase an aggregate of up to approximately 11.5 million shares of Common Stock of warrant to certain accredited investors for purchase price per Cash Pre-Funded Warrant equal to the Cash Per Share Purchase Price minus the Cash Pre-Funded Warrant Exercise Price, pre-funded on the Closin.

“On September 29, 2025, Predictive Oncology Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Cash Securities Purchase Agreement ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement (the “ Cash Offering ”) an aggregate of (i) approximately 55.2 million shares (the “ Shares ”) of common stock of the Company, par value $0.01 per share (the “ Common Stock ”), at a purchase price of $0.7751 per share (the “ Cash Per Share Purchase Price ”), and/or (ii) pre-funded warrants to purchase an aggregate of up to approximately 11.5 million shares of Common Stock (the “ Cash Pre-Funded Warrants ” and together with the Shares, the “ Cash Securities ”) to purchase shares of Common Stock (the “ Cash Pre-Funded Warrant Shares ”) at a purchase price per Cash Pre-Funded Warrant equal to the Cash Per Share Purchase Price minus the Cash Pre-Funded W”

Axe Compute Inc. issued approximately 55.2 million shares of common stock to certain accredited investors for U.S. dollars at a purchase price of $0.7751 per share.

“On September 29, 2025, Predictive Oncology Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Cash Securities Purchase Agreement ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement (the “ Cash Offering ”) an aggregate of (i) approximately 55.2 million shares (the “ Shares ”) of common stock of the Company, par value $0.01 per share (the “ Common Stock ”), at a purchase price of $0.7751 per share (the “ Cash Per Share Purchase Price ”), and/or (ii) pre-funded warrants to purchase an aggregate of up to approximately 11.5 million shares of Common Stock (the “ Cash Pre-Funded Warrants ” and together with the Shares, the “ Cash Securities ”) to purchase shares of Common Stock (the “ Cash Pre-Funded Warrant Shares ”) at a purchase price per Cash Pre-Funded Warrant equal to the Cash Per Share Purchase Price minus the Cash Pre-Funded W”

Axe Compute Inc.: Amendment to Section 3.02 of the Bylaws to limit the maximum number of directors to seven, effective September 26, 2025 (effective 2025-09-26).

“the Board approved an amendment to Section 3.02 of the Company’s Second Amended and Restated Bylaws, as amended (the “ Bylaws ”). The amendment, which became effective as of September 26, 2025, modifies Section 3.02 of the Bylaws to provide that the exact number of directors shall continue to be determined from time to time solely by resolution adopted by the affirmative vote of a majority of the entire Board, but now expressly limits the number of directors serving on the Board to a maximum of seven.”

Axe Compute Inc.: Approved and filed Certificate of Amendment to the Charter to effect a 1-for-15 reverse stock split of common stock, effective 5:00 PM ET on September 29, 2025 (effective 2025-09-29).

“the Company filed a Certificate of Amendment to the Charter with the Secretary of State of the State of Delaware on September 22, 2025, to effect the reverse stock split, effective as of 5:00 PM ET on September 29, 2025”

Axe Compute Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 8, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock. The Company has a pe”

Axe Compute Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“June 9, 2025, Predictive Oncology Inc. (the “Company”) received a letter (the “Notice) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because the Company had not regained compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Company was unable to complete its previou”

Axe Compute Inc. reported the quarter ended March 31, 2024 results: revenue $419,646, net income net loss of approximately $4.2 million, EPS $(1.04).

“share for the quarter ended March 31, 2024, was $(1.04), compared to $(0.86) for the quarter ended March 31, 2023. Q1 2024 Financial Results: The company recorded revenue of $419,646 for the first quarter of 2024, compared to $239,895 for the comparable period in 2023. Revenues for the quarter ended March 31, 2024, and March 31, 2023, were primarily derived”

Axe Compute Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at $3,696,000 (effective 2024-05-03).

“On May 3, 2024, Predictive Oncology Inc., a Delaware corporation, (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock, par value $0.01 per share, from time to time, through an “at the market offering” program pursuant to which Wainwright will act as sales agent.”

Axe Compute Inc. engaged KPMG LLP as its auditor.

“On April 3, 2024, the Audit Committee of the Board of Directors of Predictive Oncology Inc. (the "Company") approved the engagement of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm for the year ending December 31, 2024, effective immediately.”

Axe Compute Inc. dismissed BDO USA, P.C. as its auditor.

“On April 3, 2024, in connection with the engagement of KPMG as disclosed above, the Company notified BDO USA, P.C. ("BDO") that it would be dismissed as the Company's independent registered public accounting firm, effective immediately.”

Axe Compute Inc. reported the year ended December 31, 2023 results: revenue approximately $1.8 million, net income approximately $14 million, EPS $3.48 per share.

“results for the year ended December 31, 2023, and provided a corporate update. The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023. Q4 2023 and Recent Highlights: Reported meaningful progress with FluGen collaboration designed to bring a first-of-its-kind intranasal flu”

Axe Compute Inc. shareholders approved Say-on-Pay Vote at the 2023-12-28 meeting.

“the Company submitted the Say-on-Pay Vote to stockholders at its 2023 annual meeting of stockholders held on December 28, 2023.”

Pamela Bush resigned as Chief Business Officer at Axe Compute Inc..

“On February 2, 2024, Predictive Oncology Inc. (the “Company”) and Pamela Bush, Ph.D., MBA, the Company’s Chief Business Officer, agreed that Dr. Bush will leave the Company effective February 15, 2024.”

Axe Compute Inc. shareholders approved Proposal to approve a non-binding advisory resolution on the compensation of the Company’s named executive officers at the 2023-12-28 meeting.

“Proposal to approve a non-binding advisory resolution on the compensation of the Company’s named executive officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: For Against Abstain Broker Non-Votes 479,340 387,855 14,789 1,023,553”

Axe Compute Inc. shareholders rejected Proposal to approve the 2023 Equity Incentive Plan at the 2023-12-28 meeting.

“Proposal to approve the 2023 Equity Incentive Plan. The Company’s stockholders did not approve the 2023 Equity Incentive Plane. The voting results were as follows: For Against Abstain Broker Non-Votes 432,129 435,447 14,408 1,023,553”

Axe Compute Inc. shareholders approved Ratification of the appointment of BDO USA, P.C. to serve as the Company’s independent registered public accounting firm at the 2023-12-28 meeting.

“Ratification of the appointment of BDO USA, P.C. to serve as the Company’s independent registered public accounting firm. The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent auditor for 2023. The voting results were as follows: For Against Abstain 1,628,338 265,740 11,459”

Axe Compute Inc. shareholders approved Election of three Class II director nominees at the 2023-12-28 meeting.

“Election of three Class II director nominees. The Company’s stockholders elected Gregory St. Clair, Sr., Nancy Chung-Welch, Ph.D. and Matthew J. Hawryluk, Ph.D. as Class II directors”

Axe Compute Inc. reported three months ended September 30, 2023 results: revenue $715,056, EPS $0.78.

“Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023”

Josh Blacher was named as Interim Chief Financial Officer at Axe Compute Inc..

“Josh Blacher of Danforth, an experienced biotech executive who specializes in strategic finance and corporate development, has been named as the Company’s Interim Chief Financial Officer.”

Bob Myers resigned as Chief Financial Officer, Corporate Secretary and Compliance Officer at Axe Compute Inc..

“Bob Myers, the Chief Financial Officer, Corporate Secretary and Compliance Officer of Predictive Oncology Inc. (the "Company"), notified the Company of his intent to resign from the Company effective September 30, 2023 (the "Transition Date").”

Axe Compute Inc. reported three months ended June 30, 2023 results: revenue $0.5 million, net income a net loss of $3.9 million, EPS $0.98 loss per common share.

“The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023.”

Axe Compute Inc. reported financial results for three months ended March 31, 2023.

“On May 15, 2023, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the three months ended March 31, 2023.”

Veena Rao was elected as Director at Axe Compute Inc..

“Effective May 2, 2023, the Board elected Dr. Veena Rao to the Board as a Class III director.”

David S. Smith resigned as Director at Axe Compute Inc..

“On May 2, 2023, David S. Smith, JD, resigned as a director of Predictive Oncology Inc. (the “Company”), effective immediately.”

Axe Compute Inc.: Amended certificate of incorporation to effect a 1-for-20 reverse stock split of common stock (effective 2023-04-24).

“On April 19, 2023, Predictive Oncology Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), effective as of 12:01 a.m. (Delaware time) on April 24, 2023 (the “Reverse Stock Split”).”

Axe Compute Inc. shareholders approved To approve a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies for approval of the Reverse Split Proposal, in the event that there are not sufficient votes at the time of the Special Meeting to approve such proposal at the 2023-04-19 meeting.

“2. To approve a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies for approval of the Reverse Split Proposal, in the event that there are not sufficient votes at the time of the Special Meeting to approve such proposal (the “Adjournment Proposal”). For Against Abstain Broker Non-Votes 23,828,229,377 7,327,325,751 868,886,698 4,647,603,397”

Axe Compute Inc. shareholders approved To approve an amendment of the Company’s certificate of incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of not less than one-for-two (1:2) and not more than one-for-twenty-five (1:25), with the exact ratio to be set at a whole number within this at the 2023-04-19 meeting.

“1. To approve an amendment of the Company’s certificate of incorporation to effect a reverse stock split of the outstanding shares of its common stock at a ratio of not less than one-for-two (1:2) and not more than one-for-twenty-five (1:25), with the exact ratio to be set at a whole number within this range as determined by our Board of Directors (the “Reverse Split Proposal”). For Against Abstain Broker Non-Votes 29,332,407,453 6,785,775,332 548,565,438 5,000,001”

Axe Compute Inc. engaged BDO USA, LLP as its auditor.

“udit Committee and the Board of Directors approved the engagement of BDO USA, LLP (“BDO”) as the Company’s new independent registered public accounting firm to audit the Company’s consolidated financial statements commencing for the year ending December”

Axe Compute Inc. dismissed Baker Tilly US, LLP as its auditor.

“Dismissal of Independent Registered Public Accounting Firm On April 3, 2023, Predictive Oncology Inc. (the “Company”) and Baker Tilly US, LLP (“Baker Tilly”) agreed that Baker Tilly, who was previously engaged as the Company’s independent registered public accounting firm, would be dismissed as the independent registered public accounting firm of the Company in connection with auditing the Company’s consolidated financial statements commencing for the year”

Axe Compute Inc. reported the year ended December 31, 2022 results: revenue $1.5 million, net income net loss of $25.7 million, EPS $0.35.

“The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year.”

Axe Compute Inc.: Board of Directors declared a dividend of Series F Preferred Stock and established its terms, including voting rights, transferability, dividend rights, liquidation preference, and redemption provisions (effective 2023-03-16).

“On March 16, 2023, the board of directors (the “Board” ) of Predictive Oncology Inc. (the “Company” ) declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $0.01 per share ( “Series F Preferred Stock” ), for each outstanding share of the Company’s common stock, par value $0.01 per share ( “Common Stock” ) to stockholders of record at 5:00 p.m. Eastern Time on March 27, 2023 (the “Record Date” ).”

Pamela Bush was appointed as Chief Business Officer at Axe Compute Inc..

“the Board of Directors of the Company appointed Pamela Bush, Ph.D., MBA, as Chief Business Officer.”

Pamela Bush was appointed as Chief Business Officer at Axe Compute Inc..

“On January 30, 2023, the Board of Directors of Predictive Oncology Inc. (the “Company”) appointed Pamela Bush, Ph.D., MBA, age 49, as Chief Business Officer.”

Matthew J. Hawryluk, Ph.D. was elected as Class II director at Axe Compute Inc..

“Effective November 29, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected Matthew J. Hawryluk, Ph.D., to the Board as a Class II director.”

Axe Compute Inc. shareholders rejected Proposal to adjourn the Annual Meeting to a later date if necessary to solicit additional proxies for approval of the Plan Increase Proposal at the 2022-12-01 meeting.

“The Company’s stockholders did not approve a proposal to adjourn the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there were insufficient votes to approve the Plan Increase Proposal (Proposal 3) at the time of the Annual Meeting or if the Company did not have a quorum. There were 12,361,835 votes cast for the proposal; 14,035,330 votes cast against the proposal; 602,196 votes abstained, and there were 10,260,881 broker non-votes.”

Axe Compute Inc. shareholders approved Advisory vote on the frequency of future say-on-pay votes at the 2022-12-01 meeting.

“Pursuant to an advisory vote regarding the frequency of future “say-on-pay” votes, the Company’s stockholders approved conducting “say-on-pay” votes every year. There were 18,201,538 votes cast for conducting “say-on-pay” votes every year; 415,485 votes cast for conducting “say-on-pay” votes every two years; and 4,030,636 votes cast for conducting “say-on-pay” votes every three years. 2,993,547 votes abstained, and there were 11,619,036 broker non-votes.”

Axe Compute Inc. shareholders approved Advisory vote to approve the compensation of the Company’s executive officers as described in the proxy statement at the 2022-12-01 meeting.

“Pursuant to an advisory “say-on-pay” vote, the Company’s stockholders approved the compensation of the Company’s executive officers as described in the Company’s proxy statement. There were 13,336,538 votes cast for the proposal; 11,882,246 votes cast against the proposal; 422,423 votes abstained, and there were 11,619,035 broker non-votes.”

Axe Compute Inc. shareholders approved Amendment to the Company’s Amended and Restated 2012 Stock Incentive Plan to increase the reserve of shares of common stock authorized for issuance from 3,250,000 to 5,750,000 at the 2022-12-01 meeting.

“The Company’s stockholders approved a proposal to amend the Company’s Amended and Restated 2012 Stock Incentive Plan to increase the reserve of shares of common stock authorized for issuance thereunder from 3,250,000 to 5,750,000 (the “Plan Increase Proposal”). There were 14,173,961 votes cast for the proposal; 11,069,344 votes cast against the proposal; 397,902 votes abstained, and there were 11,619,035 broker non-votes.”

Axe Compute Inc. shareholders approved Ratification of the appointment of Baker Tilly Virchow Krause, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-12-01 meeting.

“The Company’s stockholders ratified the appointment of Baker Tilly Virchow Krause, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. There were 31,958,683 votes cast for the proposal; 4,713,124 votes cast against the proposal; 588,435 votes abstained, and there were no broker non-votes.”

Axe Compute Inc. shareholders approved Election of two Class I members, Chuck Nuzum and Daniel E. Handley, M.S., Ph.D., to the Company’s Board of Directors at the 2022-12-01 meeting.

“The Company’s stockholders elected two Class I members, Chuck Nuzum and Daniel E. Handley, M.S., Ph.D., to the Company’s Board of Directors. The stockholders present in person or by proxy cast the following numbers of votes in connection with the election of directors: Nominee Votes For Votes Withheld Chuck Nuzum 17,327,984 8,313,223 Daniel E. Handley, M.S., Ph.D. 15,886,840 9,754,367”

Axe Compute Inc. reported third quarter ended September 30, 2022 results: revenue $455,827.

“issues surrounding the therapeutic use of human tissue and cells. Q3 2022 Financial results The consolidated reportable segments of Predictive Oncology’s recognized revenue is $455,827 for the quarter, which has increased from $313,663 to the comparative three-month period of 2021, which depicts a revenue growth of 45%. Helomics reported an improvement in its”

Axe Compute Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“November 10, 2022, Nasdaq notified the Company that while the Company had not regained compliance with the Minimum Bid Price Requirement, it is eligible for an additional 180-day calendar period, or until May 8, 2023, to regain compliance. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency d”

David S. Smith was elected as Class III director at Axe Compute Inc..

“Effective October 19, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected David S. Smith, JD, to the Board as a Class III director.”

Raymond F. Vennare was appointed as Chairman of the Board at Axe Compute Inc..

“the Board of Directors of the Company appointed Raymond F. Vennare as Chairman of the Board, effective upon Mr. Engle’s retirement.”

Raymond F. Vennare was appointed as Chief Executive Officer at Axe Compute Inc..

“the Company appointed Raymond F. Vennare, age 70, to succeed Mr. Engle as Chief Executive Officer”